SYSTEMATIC REVIEW

Association between multimorbidity and hospitalization in older adults: systematic review and meta-analysis

Luciana Pereira Rodrigues1, Andréa Toledo de Oliveira Rezende1, Felipe Mendes Delpino2, Carolina Rodrigues Mendonça1, Matias Noll1,3,4, Bruno Pereira Nunes5, Cesar de Oliveira6, Erika Aparecida Silveira1,3

1Postgraduate Program in Health Sciences, School of Medicine, Federal University of Goiás, Goiânia, Brazil
2Department of Nursing in Public Health, Federal University of Pelotas, Pelotas, Brazil
3Federal Institute Goiano, Campus Ceres, Goiás, Brazil
4Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark
5Postgraduate Program in Nursing, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil
6Department of Epidemiology & Public Health, Institute of Epidemiology & Health Care, University College London, London, UK

Address correspondence to: E. A. Silveira, Graduate Program in Health Sciences, School of Medicine, Federal University of Goiás, Goiânia 74605-050, Brazil. Tel: (+55) 6232096146. Email: erikasil@terra.com.br

Abstract

Background: Multimorbidity is defined as the presence of multiple chronic conditions in the same individual. Multimorbidity is more prevalent in older adults and can lead to several adverse health outcomes.

Methods: We systematically reviewed evidence from observational studies to verify the association between multimorbidity and hospitalization in older adults. Furthermore, we also aimed to identify whether it changes according to gender, advanced age, institutionalization, and wealth of the country of residence. We searched the PubMed, Embase and Scopus databases from December 2020 to April 2021. The analysed outcomes were as follows: hospitalization, length of stay and hospital readmission.

Results: Of the 6,948 studies identified in the databases, 33 were included in this review. From the meta-analysis results, it was found that multimorbidity, regardless of the country’s wealth, was linked to hospitalization in older adults (OR = 2.52, CI 95% = 1.87–3.38). Both definitions of multimorbidity, ≥2 (OR = 2.35, 95% CI = 1.34–4.12) and ≥3 morbidities (OR = 2.52, 95% CI = 1.87–3.38), were associated with hospitalization. Regardless of gender, multimorbidity was associated with hospitalization (OR = 1.98, 95% CI = 1.67–2.34) and with readmission (OR = 1.07, 95% CI = 1.04–1.09). However, it was not possible to verify the association between multimorbidity and length of stay.

Conclusions: Multimorbidity was linked to a higher hospitalization risk, and this risk was not affected by the country’s wealth and patient’s gender. Multimorbidity was also linked to a higher hospital readmission rate in older adults. PROSPERO Registration (Registration number: CRD42021229328).

Keywords: multimorbidity, ageing, hospitalization, length of stay, readmission, older people

Key points

• Multimorbidity is associated with increased occurrence of hospitalizations and readmissions in older adults, regardless of the income level of the country.
• Most of the studies about the association between multimorbidity and hospitalization are concentrated in high-income countries.
• There is no gender difference in the association between multimorbidity and hospitalization outcomes.
Introduction

Multimorbidity is defined as the presence of multiple chronic conditions in the same individual [1, 2]. Its prevalence ranges from 55 to 98% in older adults [3, 4], and increase with age [5, 6]. It is estimated that 80% of the population over 75 years have at least two chronic conditions [4]. Multimorbidity leads to low quality of life and increased functional disability compared with those without chronic diseases [7] and is accompanied by polypharmacy, higher number of hospitalizations and higher mortality risk [8, 9]. The number of hospitalizations may be associated with sociodemographic variables, especially socio-economic level and the co-occurrence of chronic conditions [10].

A Swiss study identified that the chance of being hospitalized and the length of stay among older adults with multimorbidity were two times higher and five to six times higher, respectively [11]. Previous research showed that multimorbidity increased the chance of hospital readmission [12]. Moreover, hospitalization in older adults increases the risk of death [13], loss of functionality [14], stress [15], mental health problems [16], cognitive impairment and social isolation [15]. Therefore, knowing the impact of multimorbidity on hospitalization is relevant.

Although multimorbidity in older adults is related to increased hospitalization, only one systematic review published in 2011 has focused on the subject [8], addressing the presence of multiple chronic conditions, rather than multimorbidity, as this term was inserted into the Medical Subject Headings (MeSH) thesaurus only in 2018. The aforementioned review evaluated the costs and use of health services in general, such as visits to the doctor’s office, use of medication and use of hospital services. Another systematic review on multimorbidity in older adults analysed its association with hospitalization outcomes; however, that was not the focus of the study [3]. Therefore, due to the paucity of evidence [3, 8], it is relevant to investigate the impact of multimorbidity on hospitalization in older adults.

Exploring this gap is relevant in the field of public health, geriatrics and gerontology, as it could assist health services to avoid hospitalizations, readmissions and greater length of stay of older adults with multimorbidity. In this sense, the main objective of this systematic review was to analyse the impact of multimorbidity on the occurrence of hospitalization in older adults. We also aimed to assess whether this impact is affected by gender, advanced age, institutionalization and country’s per capita income, and to identify the mean length of hospitalization and the occurrence of hospital readmission.

Method

Protocol and registration

This systematic review and meta-analysis were performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology [17]. The Population, Exposure, Comparator and Outcome (PECO) structure recommended for systematic reviews [18]: 'P' (community-dwelling older adults), 'E' (multimorbidity), 'C' (associated factors) and 'O' (hospitalization). Our study was registered in PROSPERO (International Prospective Register of Systematic Reviews) (CRD42021229328). More details can be found in the systematic review protocol [19].

Search strategy and eligibility criteria

The PubMed, Embase and Scopus databases were searched by two independent researchers from December 2020 to April 2021. The strategy used MeSH terms and relevant keywords on multimorbidity, hospitalization and older adults, aiming to cover all articles on this topic (Table S1, Supplementary Material). There were no restrictions on language and year of publication of the included studies, and articles published until 30 April 2021 were considered.

The following inclusion criteria were adopted for the studies: (i) cross-sectional, cohort and case–control methodologies; (ii) use of the definition of multimorbidity as ≥2 and/or ≥ 3 chronic conditions; (iii) outcomes that included length of stay or number of hospitalizations or readmissions and (iv) participants aged 60 years or older. We chose to use the age range ≥60 years to include both the predominant definition of ‘older adult’ in developed countries (i.e. 65 years or older) [20] and that in developing countries (i.e. 60 years or older) [21].

There are different ways to operationalize and define multimorbidity. Although Fortin et al. [22] suggest the use of the term to refer to the co-occurrence of three or more chronic conditions in the same individual, to better identify individuals who need more health care, i.e. older adults, the prevalent definition is the co-occurrence of two or more chronic conditions. In a systematic review that included seventy studies, the difference in prevalence between multimorbidity ≥2 and ≥3 chronic conditions was 12.9% [23]. Thus, this review included studies that defined multimorbidity as the co-occurrence of ≥2 and ≥3 chronic conditions.

Review articles, ecological studies, case reports or series, incomplete data as well as duplicate data and unavailable data even after contacting the authors of the studies were excluded. Also excluded were studies that analysed a baseline disease or index (e.g. cancer, heart disease, depression), studies that used other definitions of multimorbidity (clusters, latent class analysis, Charlson Comorbidity Index, Cumulative Disease Rating Scale, etc.) and studies that included indigenous populations or that addressed other age groups (except if stratified to extract only the data related to older adults). Finally, conference abstracts, theses and dissertations (grey literature) were also excluded from this systematic review.

Review process

Duplicate studies were excluded using the Mendeley software. Then, two independent authors (ATOR and LPR)
Association between multimorbidity and hospitalization in older adults

Figure 1. Flow diagram of search process.

performed the reading of titles and abstracts of all selected articles using the Rayyan software [24]. After that, the selected studies were read in full and evaluated according to the eligibility criteria. Since 21 studies did not present sufficient data considered important for the research, one of the researchers contacted the authors directly to obtain such information [6, 25–44]. Disagreements were discussed and resolved by a third senior reviewer (SAE). All researchers involved in this review process have experience in conducting systematic reviews and underwent training to perform the selection of studies according to the eligibility criteria. The PRISMA flowchart of the review process is shown in Figure 1.

Data extraction and quality assessment

Data extraction was performed using a standardized form prepared by the authors, containing: author/year/location (city/country); type of study and population (number of participants, age range, follow-up time, whether institutionalized or not), definition and occurrence of multimorbidity (≥2 and/or ≥3 chronic conditions, number of chronic conditions considered, incidence or prevalence), length of stay and number of hospitalizations and readmissions (definition, prevalence and confidence interval). The measures of impact of multimorbidity on the outcomes analysed were prevalence or odds ratio (OR) with their 95% confidence intervals (CI). The data extraction Table was divided using the World Bank categorization [45], which classifies each country into high, middle and low income according to its per capita income (Table 1).

The risk of bias during the process of selection of studies was assessed using the Downs & Black Scale [46]. However, only the items related to observational studies [1–3, 5–12, 17, 19, 20, 24, 25] were applied [47]. Studies with scores higher than 70% were considered as having a low risk of bias [46].

The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) was used to evaluate the quality of the evidence [48]. In each study, the quality was attributed to the following grades: high quality (four filled
Table 1. Summary of studies that associated multimorbidity and hospitalization in the high-income countries

| Author year | Study design population | Multimorbidity definition/occurrence | Hospitalization/length of stay/readmission definition/occurrence | Impact of multimorbidity on hospitalizations/length of stay/readmission |
|-------------|-------------------------|-------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------------|
| Buja et al. 2020 | Cohort | MM: ≥ 2CC  
List of 14CC: Incidence:  
Overall: NR 2CC: 10.06%  
3CC: 21.6% | Hospital discharge records in 2013 to identify patients who experienced any of the following:  
at least one hospital admission,  
at least two hospital admissions and total number of hospital admissions | Hospitalization by multimorbidity (OR [95% CI]):  
At least 1 admission per 3CC:  
1.32 [0.91–1.93]  
At least 2 admissions per 3CC:  
1.37 [0.78–2.52] |
| Vicenza, Italy | Cohort | MM: ≥ 3CC  
List of 18CC: Incidence:  
Overall: 35.63%  
60–69 years: 41.9%  
70–79 years: 39.9%  
80–89 years: 18.2% | Hospitalizations for any cause were obtained from January 1, 2006, through December 31, 2016 | Hospitalization by multimorbidity (HR [95% CI]):  
60–69 years: 1.78 [1.64–1.94]  
70–79 years: 1.65 [1.54–1.78]  
80–89 years: 1.64 [1.46–1.83] |
| Chamberlain et al. 2019 | Cohort | MM: ≥ 2CC  
List of 9CC: Incidence:  
Overall: NR 2CC: 27.5%  
3CC: 24.9%  
Women  
2CC: 28.2%  
3CC: 24.9%  
Men  
2CC: 26.5%  
3CC: 23.0% | Long-term care: an approval for LTC admission from the municipal authorities or being at least 90 days in a residential home, service home with 24-h assistance or inpatient ward of a health centre or hospital | Hospitalization by multimorbidity (SHR [95% CI]):  
Women  
2CC: 1.43 [0.98–2.08]  
3CC: 1.64 [1.12–2.40]  
Men  
2CC: 1.52 [0.82–2.78]  
3CC: 1.57 [0.83–3.00] |
| Minnesota, USA | Cohort | MM: ≥ 2CC  
List of 9CC: Incidence:  
Overall: NR 2CC: 27.5%  
3CC: 24.9%  
Women  
2CC: 28.2%  
3CC: 24.9%  
Men  
2CC: 26.5%  
3CC: 23.0% | Hospitalizations for any cause were obtained from January 1, 2006, through December 31, 2016 | Hospitalization by multimorbidity (HR [95% CI]):  
60–69 years: 1.78 [1.64–1.94]  
70–79 years: 1.65 [1.54–1.78]  
80–89 years: 1.64 [1.46–1.83] |
| Halonen et al. 2019 | Cohort | MM: ≥ 3CC  
List of 18CC: Incidence:  
Overall: 35.63%  
60–69 years: 41.9%  
70–79 years: 39.9%  
80–89 years: 18.2% | Hospitalizations for any cause were obtained from January 1, 2006, through December 31, 2016 | Hospitalization by multimorbidity (SHR [95% CI]):  
Women  
2CC: 1.43 [0.98–2.08]  
3CC: 1.64 [1.12–2.40]  
Men  
2CC: 1.52 [0.82–2.78]  
3CC: 1.57 [0.83–3.00] |
| Tampere, Finland | Cohort | MM: ≥ 3CC  
List of 18CC: Incidence:  
Overall: 35.63%  
60–69 years: 41.9%  
70–79 years: 39.9%  
80–89 years: 18.2% | Hospitalizations for any cause were obtained from January 1, 2006, through December 31, 2016 | Hospitalization by multimorbidity (HR [95% CI]):  
60–69 years: 1.78 [1.64–1.94]  
70–79 years: 1.65 [1.54–1.78]  
80–89 years: 1.64 [1.46–1.83] |
| Wagner et al. 2019 | Cohort | MM: ≥ 2CC  
List of 9CC: Incidence:  
Overall: NR 2CC: 27.5%  
3CC: 24.9%  
Women  
2CC: 28.2%  
3CC: 24.9%  
Men  
2CC: 26.5%  
3CC: 23.0% | Hospitalizations for any cause were obtained from January 1, 2006, through December 31, 2016 | Hospitalization by multimorbidity (HR [95% CI]):  
60–69 years: 1.78 [1.64–1.94]  
70–79 years: 1.65 [1.54–1.78]  
80–89 years: 1.64 [1.46–1.83] |
| Washington, USA | Cohort | MM: ≥ 2CC  
List of 9CC: Incidence:  
Overall: NR 2CC: 27.5%  
3CC: 24.9%  
Women  
2CC: 28.2%  
3CC: 24.9%  
Men  
2CC: 26.5%  
3CC: 23.0% | Hospitalizations for any cause were obtained from January 1, 2006, through December 31, 2016 | Hospitalization by multimorbidity (HR [95% CI]):  
60–69 years: 1.78 [1.64–1.94]  
70–79 years: 1.65 [1.54–1.78]  
80–89 years: 1.64 [1.46–1.83] |
| Ensrud et al. 2018 | Cohort | MM: ≥ 2CC  
List of 31CC: Incidence:  
Overall: NR 2–4CC: 42.7% | Hospital stays and inpatient facility days for the 12-month period | Hospitalization by multimorbidity:  
2–4CC: 17.9%  
Kruskal-Wallis tests |
| USA | Cohort | MM: ≥ 2CC  
List of 31CC: Incidence:  
Overall: NR 2–4CC: 42.7% | Hospital stays and inpatient facility days for the 12-month period | Hospitalization by multimorbidity:  
2–4CC: 17.9%  
Kruskal-Wallis tests |
| Collerton et al. 2016 | Cohort | MM: ≥ 2CC  
List of 20CC: Incidence:  
Overall: 92.7%  
2CC: 26.2%  
3CC: 23.3%  
≥3CC: 23.3%  
70–79 years: 1  
80–89 years: 2  
90+ years: 3 | Data on overnight hospital admissions in a timeframe of 12 months | Hospitalization by multimorbidity:  
Any overnight hospital admission: 34.1%  
Any ‘Day Hospital’ attendance: 7.6% |
| Newcastle, England | Cohort | MM: ≥ 2CC  
List of 20CC: Incidence:  
Overall: 92.7%  
2CC: 26.2%  
3CC: 23.3%  
≥3CC: 23.3%  
70–79 years: 1  
80–89 years: 2  
90+ years: 3 | Data on overnight hospital admissions in a timeframe of 12 months | Hospitalization by multimorbidity:  
Any overnight hospital admission: 34.1%  
Any ‘Day Hospital’ attendance: 7.6% |
| Gruneir et al. 2016 | Cohort | MM: ≥ 2CC  
List of 16CC: Incidence:  
Overall: NR 2CC: 27.4%  
3CC: 45.7%  
≥3CC: 28.2%  
≥4CC: 13.87% | Data on overnight hospital admissions in a timeframe of 12 months | Hospitalization by multimorbidity:  
Any overnight hospital admission: 34.1%  
Any ‘Day Hospital’ attendance: 7.6% |
| Ontario, Canada | Cohort | MM: ≥ 2CC  
List of 16CC: Incidence:  
Overall: NR 2CC: 27.4%  
3CC: 45.7%  
≥3CC: 28.2%  
≥4CC: 13.87% | Data on overnight hospital admissions in a timeframe of 12 months | Hospitalization by multimorbidity:  
Any overnight hospital admission: 34.1%  
Any ‘Day Hospital’ attendance: 7.6% |
| Author year/ location          | Study design population’ | Multimorbidity definition/occurrence | Hospitalization/length of stay/readmission definition/occurrence | Impact of multimorbidity on hospitalizations/length of stay/readmission |
|-------------------------------|--------------------------|--------------------------------------|-------------------------------------------------------------------|-----------------------------------------------------------------------|
| **Cohort/readmission**        |                          |                                      |                                                                   |                                                                       |
| Shebeshi et al. 2020          | Cohort                   | MM: ≥2CC                             | Readmission 28 days post-discharge                                 | Regression models                                                     |
| Australia                     | 2,056 women participants | List of 6CC Incidence: NR            | Readmission incidence: 17.7%                                       |                                                                       |
| 75–95 years community         |                          |                                      | 30-day all-cause readmission                                       |                                                                       |
| Aubert et al. 2019            | Cohort                   | MM: ≥2CC                             | Readmission (median [interquartile range]): 0 [0–2]                |                                                                       |
| Switzerland/USA/Israel        | Older adults’ sample:    | 18 body system categories            | Length of stay (median [interquartile range]): 4 [3–8]            |                                                                       |
| 64 years (mean age, SD: 52–76)| NR                       | Incidence: Overall: 85.8%            |                                                                   |                                                                       |
| 1 year follow-up community/nursing home | List of 6CC Incidence: |                                      |                                                                   |                                                                       |
| Aubert et al. 2019            | Cohort                   | MM: ≥2CC                             | Readmission by multimorbidity (HR [95% CI]): >2CC: 1.21 [0.79–1.83] |                                                                       |
| Bern, Lausanne, Geneva,       | Older adults’ sample:    | 18 body system categories            | Readmission by multimorbidity (OR [95%CI]): 2CC: 1 [1.0]           |                                                                       |
| Switzerland                    | NR                       | Incidence: Overall: 79.3% (median: 68 years) | 3CC: 1.04 [0.98–1.10] |                                                                       |
| Navickas et al. 2015          | Cohort                   | MM: ≥2CC                             | Hospitalization, readmission within 30 days and length of stay    | Regression models                                                     |
| Lithuania                      | 271,866 participants     | List of 32CC Incidence:              | Hospitalization incidence: NR                                      |                                                                       |
| ≥65 years                      |                          | Overall: 2CC: 43.24%                |                                                                   |                                                                       |
| 2.5 years follow-up community |                          | 3CC: 54.12%                         |                                                                   |                                                                       |
|                                 |                          | 2CC: 22.75%                         |                                                                   |                                                                       |
|                                 |                          | 65–74 years                         |                                                                   |                                                                       |
|                                 |                          | 2CC: 15.37%                         |                                                                   |                                                                       |
|                                 |                          | 85+ years                           |                                                                   |                                                                       |
|                                 |                          | 2CC: 5.13%                          |                                                                   |                                                                       |
| **Cohort/length of stay**     |                          |                                      |                                                                   |                                                                       |
| Aubert et al. 2019            | Cohort                   | MM: ≥2CC                             | Length of stay: number of days from hospital admission to hospital discharge | Regression models |
| Bern, Lausanne, Geneva,       | Older adults’ sample:    | List of 18 body system Incidence:    | 30 days following hospital discharge                              |                                                                       |
| Switzerland                    | NR                       | Overall: 79.3% (median: 68 years)    |                                                                   |                                                                       |
|                                 |                          |                                      |                                                                   |                                                                       |
| **Cohort/hospitalization, length of stay and readmission** | Cohort | MM: ≥2CC | Hospitalizations, readmission within 30 days and length of stay | Regression models |
| Navickas et al. 2015          | 271,866 participants     | List of 32CC Incidence:              | Hospitalization incidence: NR                                      |                                                                       |
| Lithuania                      | ≥65 years                | Overall: 2CC: 43.24%                |                                                                   |                                                                       |
| 2.5 years follow-up community |                          | 3CC: 54.12%                         |                                                                   |                                                                       |
|                                 |                          | 2CC: 22.75%                         |                                                                   |                                                                       |
|                                 |                          | 65–74 years                         |                                                                   |                                                                       |
|                                 |                          | 2CC: 15.37%                         |                                                                   |                                                                       |
|                                 |                          | 85+ years                           |                                                                   |                                                                       |
|                                 |                          | 2CC: 5.13%                          |                                                                   |                                                                       |
| **Cross-sectional/hospitalization** | Cross-sectional         | MM: ≥2CC                             | Inpatient visits over the past one year                           | Regression models |
| Kim et al. 2020               | Older adults’ sample:    | List of 28CC Prevalence: NR          | Hospitalization prevalence: NR                                     |                                                                       |
| South Korea                   | ≥65 years community      |                                      | Number of hospital admissions during September 1, 2013, and August 31, 2014 |                                                                       |
| Mitsutake et al. 2019         | Cross-sectional         | MM: ≥2CC and ≥3CC                    | Hospitalization prevalence: NR                                     |                                                                       |
| Tokyo, Japan                  | 1,311,116 participants   | List of 21CC Prevalence:             | Number of hospital admissions during September 1, 2013, and August 31, 2014 |                                                                       |
| 75 years community            |                          | Overall: 2CC: 40.2%                 | Hospitalization prevalence: NR                                     |                                                                       |
|                                 |                          | 3CC: 74.12%                         | Number of hospital admissions during September 1, 2013, and August 31, 2014 |                                                                       |
|                                 |                          | 2CC: 22.75%                         | Hospitalization prevalence: NR                                     |                                                                       |
|                                 |                          | 65–74 years                         | Number of hospital admissions during September 1, 2013, and August 31, 2014 |                                                                       |
|                                 |                          | 2CC: 15.37%                         | Hospitalization prevalence: NR                                     |                                                                       |
|                                 |                          | 85+ years                           | Hospitalization prevalence: NR                                     |                                                                       |
|                                 |                          | 2CC: 5.13%                          | Hospitalization prevalence: NR                                     |                                                                       |
|                                 |                          | 65–74 years                         | Hospitalization prevalence: NR                                     |                                                                       |
|                                 |                          | 2CC: 15.37%                         | Hospitalization prevalence: NR                                     |                                                                       |
|                                 |                          | 85+ years                           | Hospitalization prevalence: NR                                     |                                                                       |
|                                 |                          | 2CC: 5.13%                          | Hospitalization prevalence: NR                                     |                                                                       |
|                                 |                          | 65–74 years                         | Hospitalization prevalence: NR                                     |                                                                       |
|                                 |                          | 2CC: 15.37%                         | Hospitalization prevalence: NR                                     |                                                                       |
|                                 |                          | 85+ years                           | Hospitalization prevalence: NR                                     |                                                                       |

**Continued**
| Author year location | Study design population’ | Multimorbidity definition/occurrence | Hospitalization/length of stay/ readmission definition/occurrence | Impact of multimorbidity on hospitalizations/length of stay/readmission |
|----------------------|--------------------------|-------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------------|
| Rodrigues et al. 2018 | Cross-sectional 2,393 participants ≥ 65 years community | MM: ≥2CC List of 12CC | Hospitalization in the previous 12 month | Hospitalization prevalence 25.8% |
| Portugal (the mainland, Azores, and Madeira) | | Prevalence: Overall: 78.3% | | |
| Wolff et al. 2015 USA | Cross-sectional 1,217,103 participants ≥ 65 years community | MM: ≥2CC and ≥ 3CC List of 16CC Prevalence: Overall: NR 2CC: 65% 3CC: 43% | Hospitalizations for ambulatory care sensitive conditions within a year | Hospitalization prevalence: NR Hospitalization over the preceding 12 months |
| Nägga et al. 2012 Linkoping, Sweden | Cross-sectional 496 participants ≥ 85 years community | MM: ≥2CC List of 14CC Prevalence: Overall: 68% | Hospitalization prevalence: NR | |
| Glynn et al. 2011 Ireland | Cross-sectional 2,000 participants ≥ 60 years community | MM: ≥2CC List of 9 system ICPC-2 coding of chronic diseases Prevalence: Women Overall: 60.23% 60–69 years: 69.4% 70–79 years: 84.1% 80+ years: 89.0% Men Overall: 60.65% 60–69 years: 66.2% 70–79 years: 82.4% 80+ years: 88.2% | Hospital admission in the previous 12 months | Hospitalization prevalence: NR |
| Cross-sectional/length of stay | | | Inpatient care during the three-month period prior to the interview | Length of stay prevalence: NR |
| Picco et al. 2016 Singapore | Cross-sectional 2,565 participants ≥ 60 years community | MM: ≥2CC List of 10CC Prevalence: Overall: 51.5% 60–74 years: 47.2% 75–84 years: 65.3% 85+ years: 59.8% | | |
| Wister et al. 2016 Canada/Australia | Cross-sectional 9,886 participants (Canada): 1,858 (Australia) ≥ 65 years community | MM: ≥2CC List of 7CC Prevalence: NR | Length of stay in the last year | Length of stay prevalence: NR |
| Cross-sectional/ readmission | | | | |
| Conner et al. 2019 USA | Cross-sectional 2,375,331 participants ≥ 65 years community | MM: ≥2CC List of 25CC Prevalence: Overall: 15% 2CC: 5.7% 3CC: 9.3% | 30-day all-cause unplanned hospital readmissions Prevalence (% [95%CI]): 11.9 [11.7–12.0] | |

Continued
Association between multimorbidity and hospitalization in older adults

Table 1. Continued

| Author year location | Study design population | Multimorbidity definition/occurrence | Hospitalization/length of stay definition/occurrence | Impact of multimorbidity on hospitalizations/length of stay definition/occurrence |
|----------------------|-------------------------|-------------------------------------|------------------------------------------------------|--------------------------------------------------------------------------------|
| Lochner et al. 2013  | Cross-sectional         | MCC: ≥2CC                           | Hospitalization, readmission and length of stay      | Readmission by multimorbidity: NR |
| USA                  | Cross-sectional         | MCC: ≥2CC                           | Hospitalization, readmission and length of stay      | Regression models |
| Cross-sectional/hospitalization and length of stay | MM: ≥2CC | Number of hospitalizations, if any, and the mean length of hospital stay in a year | Hospitalizations: 1.5 (0.9) |
| Bhäuler et al. 2015  | Cross-sectional         | MM: ≥2CC                           | Hospitalization, readmission and length of stay      | Regression models |
| Switzerland          | 229,493 participants    | MCC: ≥2CC                           | Hospitalization, readmission and length of stay      | Regression models |
| ≥65 years community  |                         | Overall: NR                         | Hospitalization, readmission and length of stay      | Regression models |

| Abbreviations: |                  |
|----------------|-----------------|
| CC:            | chronic conditions |
| CI:            | confidence interval |
| HR:            | hazard ratio |
| MM:            | multimorbidity |
| OR:            | odds ratio |
| SE:            | standard error |
| SHR:           | sub hazard ratio |
| Std Error:     | standard error |

### Statistical analysis

The impact of multimorbidity on the occurrence of hospitalization, readmission and length of stay in older adults was summarized, as well as the meta-analysis of the mean length of stay and the occurrence of hospital readmission. For both, meta-analyses, i.e. the impact of multimorbidity on the occurrence of hospitalization and the analysis of the occurrence of hospital readmission, a random effects model forest plot was built using OR results and their respective 95% CIs. The combined results were stratified according to socio-economic level (upper middle-income and lower middle-income countries).

Studies that reported data as hazard ratio (HR) or relative risk (RR) were converted into ORs, using the following formula: \( \text{OR} = (1 - p) \times \text{RR} / (1 - \text{RR} \times p) \), where RR or HR is the relative risk or hazard ratio, respectively, OR is the odds ratio and \( p \) is the rate of the event in the control group [49]. A random effects model was used to perform the analyses. The results were reported as OR and their respective 95% CI. When possible, we considered the adjusted values of the studies for inclusion in the meta-analysis. Statistical analyses were conducted with the R language, version 4.1.0, using the miniMeta package.

### Heterogeneity assessment and additional analyses

The Higgins I² statistic was calculated to estimate statistical heterogeneity among studies, considering values above 50% and \( p = 0.05 \) as high heterogeneity [50], and forest plots were constructed to graphically display effect sizes among studies [51]. Publication bias was assessed using funnel plots [52] and Egger’s test of funnel plot asymmetry [53].

### Results

This review identified 6,948 articles, and after exclusion of duplicates, 4,270 articles remained. Of these, after applying the eligibility criteria, 288 were selected for full-text reading, after which a total of 51 articles were selected. However, as 21 of these required additional data [6, 25–44], we contacted the respective authors, and obtained eight responses [6, 29, 30, 37, 40, 44, 46, 47]. Thus, 33 articles were included in this systematic review [11, 12, 27, 34, 54–82], of which 16 were included [12, 27, 34, 54, 56, 58–60, 64, 68, 69, 71, 74, 77–79] in the meta-analysis (Figure 1).

There were 23 studies [11, 12, 27, 34, 54–65, 73, 76–81] from high- and 10 studies [66–72, 74, 75, 82] from upper middle- and lower-income countries. Twenty-one studies (63.6%) were cross-sectional [11, 27, 34, 56–61, 63–65, 67–72, 74, 75, 82] and 12 cohorts [12, 54, 55, 62, 66, 73, 76–81], with a follow-up ranging from 1 to 11 years. The number of individuals in the studies ranged from 496 to 31.6 million [59, 65] (Tables 1 and 2).

Twenty-three articles considered multimorbidity as the presence of two or more chronic conditions [11, 12, 27, 34, 55, 57, 59–65, 67, 68, 70, 72–75, 77, 81, 82], one article as three or more [79] and nine used both definitions [54, 56, 58, 66, 69, 71, 76, 78, 80]. Considering the outcomes, 23 studies evaluated the association of multimorbidity with hospitalization [27, 34, 54, 56–60, 62, 68–76, 78–80, 82], four with readmission [12, 64, 65, 77] and three with length of stay [61, 63, 81]. Two articles evaluated two outcomes: hospitalization and length of stay [11, 66], and one article analysed hospitalization, length of stay and readmission [55] (Tables 1 and 2).

The list of diseases ranged from 6 [77] to 40 [66] diseases since 54% of the studies used 10–20 diseases [27, 57, 59, 61, 65, 68, 70, 71, 73, 74, 76, 78, 79, 82], 25% used 21 or more diseases [11, 34, 55, 56, 62, 66, 72], 21% used 6–9 diseases [54, 63, 67, 69, 77, 80] and five studies did not...
Table 2. Summary of studies that associated multimorbidity and hospitalization in the upper middle- and lower middle-income countries

| Author year | Study design  | Multimorbidity definition/occurrence | Hospitalization/length of stay | Impact of multimorbidity on hospitalizations |
|-------------|---------------|--------------------------------------|--------------------------------|--------------------------------------------|
| **Upper middle income** | | | | |
| Lai et al. 2019 | Cohort | ≥2CC | MM: ≥2CC | Number of annual hospital admissions, and annual number of length of stay | Regression models adjusted for sex, comprehensive social security assistance recipient status, elderly home residential status, and number of days survived |
| Hong Kong, China | 94,225 participants | 60–64 years 2CC: 6.8%/≥3CC: 5.0% | Hospitalization incidence: NR | Hospitalization by multimorbidity follow-year 9 (RR [95% CI]) |
| | ≥60 years 9 years follow-up community | 65–69 years 2CC: 11.2%/≥3CC: 5.0% | Length of stay incidence: NR | 65–74 years |
| | | 70–74 years 2CC: 16.6%/≥3CC: 10.0% | | 2CC: 0.54 [0.48–0.61] |
| | | 75–79 years 2CC: 18.7%/≥3CC: 20.5% | | ≥3CC: 0.64 [0.54–0.75] |
| | | 80–84 years 2CC: 15.4%/≥3CC: 19.3% | | 75+ years |
| | | 85–89 years 2CC: 9.2%/≥3CC: 12.2% | | 2CC: 0.40 [0.36–0.45] |
| | | 90–94 years 2CC: 4.5%/≥3CC: 5.0% | | ≥3CC: 0.53 [0.46–0.62] |
| | | 95–99 years 2CC: 1.1%/≥3CC: 1.2% | | Length of stay by multimorbidity follow-year 9: |
| | | 100+: 2CC: 0.3%/≥3CC: 0.2% | | 65–74 years |
| | | | | 2CC: 1.70 [1.51–1.92] |
| | | | | ≥3CC: 2.31 [1.92–2.77] |
| | | | | 75+ years |
| | | | | 2CC: 2.08 [1.83–2.35] |
| | | | | ≥3CC: 2.26 [1.91–2.67] |
| **Cross-sectional/hospitalization** | | | | |
| Garcia-Ramirez et al. 2020 | Cross-sectional | MM: ≥2CC | Hospitalization prevalence: 12.9% | Hospitalization by multimorbidity (OR [SE]): 2.59, 0.432 |
| Colombia | 23,694 participants | List of 7CC Prevalence: Overall: 45.63% | Inpatient visits in the last year | Regression models |
| Li et al. 2020 | Cross-sectional | MM: ≥2CC | Hospitalization prevalence: NR | Hospitalization by multimorbidity: 24.6% Truncated negative binomial model |
| China | 5,166 participants | List of 14CC Prevalence: Overall: NR 65–69 years: 39.5% | | Number of hospitalization (mean [SD]): 1.63 [1.14] |
| | ≥65 years community-dwelling | 70–74 years: 28.2% 75–79 years: 17.4% 60–74 years: 14.9% | | Regression models adjusted for age, gender, marital status, education and living arrangement |
| Cheung et al. 2019 | Cross-sectional | MM: ≥2CC | Hospital admission in the past 12 months | Hospitalization by multimorbidity (OR [95% CI]): |
| Hong Kong, China | 2,618 participants | List of 7CC Prevalence: Overall: 41.8% | Hospitalization prevalence: 23.6% | Overall: 1.25 [1.04–1.51] |
| | ≥60 years community-dwelling | 2CC: NR | | 2 CC: 1.74 [1.26–2.40] |
| | | 3CC: 10.4% | | 3CC: 2.82 [1.93–4.12] |
| Wang et al. 2018 | Cross-sectional | MM: ≥2CC | Annual hospitalization | Hospitalization by multimorbidity: |
| Shenzhen City, China | 2,609 participants | List of 17CC Prevalence: Overall: 45.06% | Hospitalization prevalence: 10.50% | 15.9% |
| | ≥60 years community-dwelling | | | | |
| Nunes et al. 2017 | Cross-sectional | MM ≥2CC and ≥3CC | Hospitalization in the last year | Regression models adjusted for gender, age, skin colour, marital status, economic classification and education |
| Bagé, Brazil | 1,593 participants | List of 17CC Prevalence (%) [95%CI]: Overall: NR | Hospitalization prevalence (%) [95%CI]: 17.7 [15.8–19.6] | Hospitalization by multimorbidity (PR [95%CI]): |
| | ≥60 years community-dwelling | 2CC: 81.3% [79.3–83.3] | | ≥2CC: 1.75 (1.21–2.51) ≥3CC: 1.94 (1.46–2.56) |
| | | 3CC: 64.0% [61.5–66.4] | | | |
| Nunes et al. 2015 | Cross-sectional | MM ≥2 and ≥3 | Hospitalization in the 12 months | Hospitalization by multimorbidity (%) [95%CI]: |
| Bagé, Brazil | 1,593 participants | List of 17CC Prevalence (%) [95%CI]: Overall: NR | Hospitalization prevalence: NR | ≥2CC: 88.2 [84.3–92.2] |
| | ≥60 years community-dwelling | 2CC: 81.3% [79.3–83.3] | | ≥3CC: 76.5 [71.2–81.7] |
Association between multimorbidity and hospitalization in older adults

| Author year | Location | Study design | Multimorbidity definition | Hospitalization/length of stay/readmission | Impact of multimorbidity on hospitalizations |
|-------------|----------|--------------|---------------------------|--------------------------------------------|-------------------------------------------|
| Lower middle income | Cross-sectional/hospitalization |
| Pati et al. 2020 | Odisha, India | Cross-sectional | Older adults' sample: NR | Inpatient admissions in the last 12 months | Regression models adjusted for gender, ethnicity, socio-economic status, highest education, marital status |
| | | List of 21CC | Overall: NR | NR | Hospitalization prevalence: NR |
| | | Prevalence (% [95%CI]): | 60–69 years: 6.9 [28.1–45.8] | 70+ years: 4.4 [33.0–55.8] | Hospitalization by multimorbidity (OR [95%CI]): 2.32 [1.82–2.95] |
| Mini et al. 2017 | India | Cross-sectional | 9,852 participants | Hospitalization in the past 1 year | Regression models adjusted for age-sex |
| | | List of 12CC | Overall: 30.7% | Hospitalization prevalence: NR | Hospitalization by multimorbidity (OR [95%CI]): |
| | | Prevalence: | | | Any visit |
| | | | | | 61–70 years: 1.23 [0.91–1.65] |
| | | | | | 71+ years: 1.42 [1.02–2.00] |
| | | | | | Number of visits (IRR [95% CI]): |
| | | | | | 61–70 years: 1.23 [0.88–1.72] |
| | | | | | 71 + years: 1.53 [1.01–2.32] |
| | | | | | Regression models |
| Marthias et al. 2021 | Indonesia | Cross-sectional | 2,712 participants | Inpatient visits in the last 12 months | |
| | | List of 14CC | Overall: | | |
| | | Prevalence (% [95%CI]): | 61–70 years: 21.9 [19.2 to 24.8] | | |
| | | | 71 + years: 25.2 [20.6 to 30.4] | | |
| | | | | | |

**Table 2.** Continued

**Abbreviations:** CC: chronic conditions, CI: confidence interval, HR: hazard ratio, IRR: incidence rate ratio, MM: multimorbidity, OR: odds ratio, SE: standard error. NR: not reported *The sample included in the table was the age group 60 years or older.

The five most frequently diseases were: diabetes (in 27 of the 33 studies), hypertension (in 27 of the 33 studies), cancer (in 26 of the 33 studies), coronary heart disease (in 25 of the 33 studies) and stroke (in 23 of the 33 studies).

Administrative data (11 studies) [11, 55, 57, 58, 62, 64, 65, 76–78], self-report (15 studies) [19, 34, 59, 61, 63, 67–72, 74, 75, 80, 82] and medical report (7 studies) [12, 54, 60, 66, 73, 79, 81] were the multimorbidity data sources reported. Among these, self-report was the most used; followed by administrative data and medical reports. With regards to the measures adopted to assess multimorbidity, this review found: Disease Count (30 articles), ACG system (2 articles) [58, 78] and Latent Class Analysis (1 article) [41].

The scores obtained in the Downs & Black Scale ranged from 53.8% to 100% (Appendix 1), and 30 studies included in the review had scores above 70%, indicating a low risk of bias. Regarding the evaluation of the methodological quality through GRADE, 8 studies presented moderate quality [12, 61–63, 69, 71, 72, 76], 20 presented low quality [11, 27, 54, 55, 57–60, 66–68, 70, 74, 75, 78, 80, 81] and 5 presented very low quality [34, 56, 64, 65, 79]. Most studies (29; 87.9%) declared no conflict of interest and 24 (72.7%) reported ethical approval. Related to the funnel plot analysis, the Egger test showed no asymmetry across the studies (p = 0.1) (Appendix 2).

For the 16 articles included in the meta-analysis [12, 27, 34, 54, 56, 58–60, 64, 68, 69, 71, 74, 77–79] the OR of the association between multimorbidity and hospitalization according to the country's income was 2.52 (1.87–3.38) (Figure 2, Appendix 2). When stratified by per capita income, only one study [83] did not show an association between multimorbidity and hospitalization. When stratified by two and three chronic conditions, only one article [78] found no significant association between multimorbidity ≥3 and hospitalization (Figure 3). In the meta-analysis of the association between hospitalization and multimorbidity ≥2 chronic conditions, the OR was 2.35 (95%CI: 1.34; 4.12, I²: 99%), while for ≥3 chronic conditions, it was 2.77 (95%CI: 1.83–4.20, I²: 100%) (Figure 3).

Focusing on length of stay, six studies [11, 55, 61, 63, 66, 81] evaluated this outcome. However, it was not possible to perform a meta-analysis due to insufficient data for pooling. Three studies [11, 55, 61] used the mean length of stay associated with multimorbidity ≥2CC ranging from 2.7 [61] to 14.3 [11]. Two studies applied the odds ratio as a measure of association, ranging from 1 [1] [81] to 1.60 [1.31, 1.96] [63]. Only one study used the relative risk and identified an increase from 1.70 [1.51–1.92] among those aged 65 to 74 years with 2CC to 2.31 [1.92–2.77] among those in the same age group with ≥3CC [66].

Multimorbidity was associated with hospitalization in older adults from both genders, OR = 2.10 (95%CI: 1.44; 3.08, I²: 96%) in women and 1.95 (95%CI: 1.52; 2.49, I²: 92%) in men (Figure 4). Three studies were included in the meta-analysis on the association between multimorbidity and readmission in older adults (69,82,83), with OR = 1.07 (95%CI: 1.04; 1.09 F: 0%) (Figure 5).
Figure 2. Forest plot of odds ratio of the association between multimorbidity and hospitalization in older adults stratified by income.

Discussion

To the best of our knowledge, this is the first meta-analysis to assess the impact of multimorbidity on hospitalization and readmission of older adults in high-, middle-, and low-income countries. In this systematic review and meta-analysis, we found a 2.5-fold positive risk of association between multimorbidity and hospitalization, and this risk was similar in studies that analysed ≥2 and ≥3 morbidities, regardless of income level and gender. Multimorbidity increased the risk of hospital readmissions. The studies that analysed length-of-stay associated with multimorbidity did not use measures of association, making it impossible to perform a meta-analysis.

We found that in high-, middle- and low-income countries there was a positive association between hospitalization and multimorbidity with a 2.5 times higher risk. Previous systematic reviews also identified an association between multimorbidity and hospitalization in older adults [3] and use and cost of health services in older adults with multiple chronic conditions [8]. However, they [3, 8] included only studies from high-income countries. A report conducted by the Academy of Medical Sciences of the United Kingdom in 2018 observed that the increase in the number of chronic conditions is associated with hospitalization in low- and middle-income countries; nonetheless, there were still few studies in these countries when compared to those of high income [14].

International reports and guidelines have discussed interventions on how to manage multimorbidity in older adults, such as the World Health Organization guideline [83] and the Academy of Medical Sciences report [14]. According to WHO, for the safe and effective management of multimorbidity is necessary a primary care system that provides
Association between multimorbidity and hospitalization in older adults

| Study                                    | Odds Ratio | OR   | 95%-CI | Weight |
|------------------------------------------|------------|------|--------|--------|
| **≥ 2 Morbidities**                      |            |      |        |        |
| Glynn et al. 2011 [61] *                 | 1.86       | (1.18 - 2.94) | 4.3%   |
| Nägga et al. 2012 [60]                   | 2.10       | (1.51 - 2.91) | 4.5%   |
| Wolff et al. 2015 [59]                   | 18.10      | (15.79 - 20.75) | 4.7%   |
| Nunes et al. 2017 [72] *                 | 1.96       | (1.22 - 3.15) | 4.2%   |
| Mini et al. 2017 [75] *                  | 2.32       | (1.82 - 2.95) | 4.6%   |
| Rodrigues et al. 2018 [28] *             | 1.91       | (1.39 - 2.62) | 4.2%   |
| Cheung et al. 2019 [70] *                | 1.29       | (1.00 - 1.66) | 4.5%   |
| Cheung et al. 2019 [70] *                | 1.48       | (1.14 - 1.93) | 4.6%   |
| Wagner et al. 2019 [55] *                | 1.83       | (1.38 - 2.37) | 4.6%   |
| Wagner et al. 2019 [55] *                | 1.86       | (1.55 - 2.23) | 4.7%   |
| Li et al. 2020 [69]                      | 2.67       | (1.87 - 3.81) | 4.4%   |
| Li et al. 2020 [69]                      | 4.74       | (2.63 - 8.54) | 4.0%   |
| Kim et al. 2020 [35]                     | 1.53       | (1.36 - 1.73) | 4.7%   |
| **Random-effects model**                 | 2.35       | (1.34 - 4.12) | 58.5%  |
| Heterogeneity: $I^2 = 99\%$, $p < 0.01$ |            |      |        |        |
| **≥ 3 Morbidities**                      |            |      |        |        |
| Glynn et al. 2011 [61] *                 | 2.12       | (1.33 - 3.38) | 4.3%   |
| Wolff et al. 2015 [59]                   | 36.43      | (31.81 - 41.73) | 4.7%   |
| Nunes et al. 2017 [72] *                 | 2.25       | (1.55 - 3.27) | 4.4%   |
| Chamberlain et al., 2019 [80] *          | 1.73       | (1.64 - 1.83) | 4.8%   |
| Mitsutake et al. 2019 [57] *             | 1.77       | (1.71 - 1.84) | 4.8%   |
| Mitsutake et al. 2019 [57] *             | 1.35       | (1.31 - 1.39) | 4.8%   |
| Wagner et al. 2019 [55] *                | 2.93       | (2.51 - 3.42) | 4.7%   |
| Wagner et al. 2019 [55] *                | 3.03       | (2.53 - 3.63) | 4.7%   |
| Buja et al. 2020 [79] *                  | 1.41       | (0.99 - 2.01) | 4.4%   |
| **Random-effects model**                 | 2.77       | (1.83 - 4.20) | 41.5%  |
| Heterogeneity: $I^2 = 100\%$, $p = 0$   |            |      |        |        |
| **Random-effects model**                 | 2.52       | (1.87 - 3.38) | 100.0% |
| Heterogeneity: $I^2 = 99\%$, $p < 0.01$ |            |      |        |        |

Figure 3. Forest plot of odds ratio of the association between multimorbidity and hospitalization in older adults stratified by ≥2 and ≥3 morbidities.

Comprehensive and integrating care performed by the same team, considering multiple chronic conditions. In this sense, the guideline discusses the importance of training health professionals through the implementation of the multimorbidity theme at undergraduate and graduate levels. This will improve and avoid fragmentation of health care for older adults with multimorbidity [83]. The Academy of Medical Sciences report raised important concerns about the fact that health systems and guidelines are directed to the treatment of a single chronic disease and provide recommendations for their use. It demonstrates that there is a lack of preventive strategies specifically for the management and treatment of older adults with multimorbidity [14].

Most studies (70%) included in this systematic review were conducted in high-income countries, which reflects the lower support and funding for research in middle- and low-income countries, such as Brazil, where the government does not currently support or encourage science [84]. It is also important to acknowledge that studies on multimorbidity and hospitalization are increasingly relevant both due to population ageing and the advent of the COVID-19 pandemic, which increases hospitalization and mortality in those with multimorbidity [85, 86].

Our study has shown that both definitions of multimorbidity, i.e. ≥2 and ≥3 morbidities, were associated with hospitalization in older adults. Another systematic review, despite not having used the same definitions of multimorbidity as the ones used in our study, found that as the number of diseases in the same individual increased, the probability of hospitalization also increased [8]. This finding highlights the importance of health professionals being prepared to
provide integrated care to older adults with multimorbidity to mitigate its adverse health outcomes.

Only 31% of the included studies presented information on the association between multimorbidity and hospitalization by gender. This association was positive regardless of gender and without significant variation between men and women. A previous systematic review that included 35 studies on the association between use and costs of health services among older people with multiple chronic conditions did not find an association between gender and hospitalization [8]. We observed that, despite the prevalence of multimorbidity in older adults being higher in women [3, 23], the occurrence of hospitalization due to multimorbidity was not different between genders. Due to the small number of studies stratified by gender in this meta-analysis, these findings should be interpreted with caution.

One of the objectives of our study was to verify whether the association between multimorbidity and hospitalization changed by age given the high prevalence of multimorbidity in older adults, especially those aged 85 and older [26]. However, due to the heterogeneity of age groups included in the studies, it was not possible to perform a meta-analysis.

Multimorbidity increased hospital readmission in older adults by 1.07 times. These results corroborate the findings of another systematic review that identified that multiple chronic conditions increase the probability of unplanned hospital readmission in older adults.
hospital readmissions [8]. Although in this meta-analysis we observed a positive association between readmission and multimorbidity, this information should be interpreted cautiously due to the number of studies. In addition, methodological differences regarding the definition of readmission in the studies may have also interfered in the results.

Length of stay was one of the outcomes analysed in this review, but it was observed in only seven of the 33 studies included. The studies on length of stay did not present measures of association with multimorbidity in older adults, only means and standard deviations. Therefore, it was not possible to assess the association with multimorbidity. In addition, some studies stratified this association by age group [55, 63, 66] and different definitions of multimorbidity (≥2 or ≥3 chronic conditions) [11, 55, 61, 81].

Cardiometabolic diseases and cancer were the most used conditions. The heterogeneity related to diseases used to measure and assess multimorbidity is widely discussed by the scientific community [87]. This highlights the lack of consensus on the pre-defined criteria for choosing the list of diseases since some are selected based on data availability [88], prevalence [89] and other reasons. With regard to the data source, self-report was the most used method, which could be explained by the fact that population-based samples tend to be large and/or when other data sources are not available [22].

A few limitations should be acknowledged. First, the impossibility of performing a meta-analysis for several outcomes analysed (readmission and length of stay). Second, the heterogeneity of the results found. Thus, some findings need to be interpreted with caution given the low number of studies found.

The strengths of this systematic review are the use of scales to verify the methodological quality and risk of bias of the included studies and absence of language and year of publication restrictions, broad list of descriptors and databases used, as well as the performance of a meta-analysis. Other positive aspects of our review were: conducting a supplementary search, tracking citations in the reference list of the included studies and relevant systematic reviews, and Google Scholar searches; using two definitions of multimorbidity (i.e. ≥2 and/or ≥3 chronic conditions), making the study broader; and using the age range ≥60 years to include both definitions from developed and developing countries.

**Directions for future studies**

As most studies included were from high-income countries, further studies in low- and middle-income countries should be prioritized, especially among women [14, 23]. In view of the high prevalence of multimorbidity worldwide and its impact on hospitalization, further studies are needed to assist in the construction of public policies for better prevention, treatment and continuity of care. We also reinforce the importance of stratification by gender in studies on multimorbidity and hospitalization. Future research should also evaluate the impact of multimorbidity on hospitalization, readmission and length of stay in older adults, as this information is relevant for planning health services and care in the prevention of diseases in this population, as well as economic costs with health. This systematic review evaluates the impact of multimorbidity on hospitalization, readmission and length of stay through a simple disease count. Future research should explore these associations by applying other measures available to assess multimorbidity, such as specific disease clusters or patterns.

**Conclusion**

In this systematic review and meta-analysis, multimorbidity (≥2 and ≥3 morbidities) was associated with a higher risk of hospitalization, regardless of the country’s income level and patients’ gender. The occurrence of multimorbidity was associated with higher hospital readmission in older adults. It was not possible to verify if there was an association between multimorbidity and length of stay.

**Supplementary Data:** Supplementary data mentioned in the text are available to subscribers in *Age and Ageing* online.

**Declaration of Conflicts of Interest:** None.

**Declaration of Sources of Funding:** This work was supported by the Economic and Social Research Council (ESRC) [grant number ES/T008822/1].

**References**

1. van den Akker M, Buntinx F, Metsemakers JF, Roos S, Knoottenurus JA. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 1998; 51: 367–75.
2. Salive ME. Multimorbidity in older adults. Epidemiol Rev 2013; 35: 75–83.
3. Marengoni A, Angleman S, Melis R et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev 2011; 10: 430–9.
4. Pefoyo AJ, Bronskill SE, Gruneir A et al. The increasing burden and complexity of multimorbidity. BMC Public Health 2015; 15: 415. https://doi.org/10.1186/s12889-015-1733-2.
5. Salisbury C, Johnson L, Purdy S, Valderas JM, Montgomery AA. Epidemiology and impact of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract 2011; 61: e12–21.
6. Lee JT, Hamid F, Pati S, Atun R, Millett C. Impact of non-communicable disease multimorbidity on healthcare utilisation and out-of-pocket expenditures in middle-income countries: cross sectional analysis. PLoS One 2015; 10: e0127199. https://doi.org/10.1371/journal.pone.0127199.
7. Williams JS, Egide LE. The association between multimorbidity and quality of life, health status and functional disability. Am J Med Sci 2016; 352: 45–52.
8. Lehnert T, Heider D, Leicht H et al. Review: health care utilization and costs of elderly persons with multiple chronic conditions. Med Care Res Rev 2011; 68: 387–420.
L. P. Rodrigues et al.

9. Nunes BP, Flores TR, Mielke GI, Thomé E, Facchini LA. Multimorbidity and mortality in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr 2016; 67: 130–8.

10. Andersen R, Newman JF. Societal and individual determinants of medical care utilization in the United States. Milbank Q 2005; 83: 1–28. https://doi.org/10.1111/j.1468-0009.2005.00428.x.

11. Bähler C, Huber CA, Brünger B, Reich O. Multimorbidity, health care utilization and costs in an elderly community-dwelling population: a claims data based observational study. BMC Health Serv Res 2015; 15: 1–12. https://doi.org/10.1186/s12913-015-0698-2.

12. Aubert CE, Schnipper JL, Fankhauser N et al. Patterns of multimorbidity associated with 30-day readmission: a multinational study. BMC Public Health 2019; 19: 1–8. https://doi.org/10.1186/s12889-019-7066-9.

13. Cornette P, Swine C, Malhomme B, Gillet J-B, Meert P, D’Hooore W. Early evaluation of the risk of functional decline following hospitalization of older patients: development of a predictive tool. Eur J Public Health 2006; 16: 203–8.

14. MacMahon S. Multimorbidity: a priority for global health research. Academy of Medical Sciences 2018; April: 4–125.

15. da Rosa PH, Beuter M, Benetti ERR, Bruinisma JL, Venturini L, Backes C. Stressors factors experienced by hospitalized elderly from the perspective of the Neuman systems model. Esc Anna Nery 2018; 22: 1–9.

16. Carvalho TC, do Valle AP, Jacinto AF, de Sá Mayoral VF, Boas PJFV. Impacto da hospitalização na funcionalidade de idosos: estudo de coorte. Rev bras geriatr gerontol 2018; 21: 134–42.

17. Moher D, Shamseer L, Clarke M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4: 1. https://doi.org/10.1186/2046-4053-4-1.

18. Morgan RL, Whaley P, Thayer KA, Schünnemann HJ. Identifying the PECO: a framework for formulating good questions to explore the association of environmental and other exposures with health outcomes. Environ Int 2018; 121: 1027–31.

19. Rodrigues LP, de Oliveira Rezende AT, Moura L d ANE et al. What is the impact of multimorbidity on the risk of hospitalisation in older adults? A systematic review study protocol. BMJ Open 2021; 11: e049974. https://doi.org/10.1136/bmjopen-2021-049974.

20. WHO. Active ageing: A policy framework. Geneva: World Health Organization, Switzerland, 2002.

21. Federal S. Estatuto do idoso. Brasília (DF): Senado Federal, 2003.

22. Fortin M, Stewart M, Poitras M, Maddocks H. A systematic review of prevalence studies on multimorbidity: toward a more uni-form methodology. Ann Fam Med 2012; 10: 142–51.

23. Nguyen H, Manolova G, Daskalopoulou C, Vitoratou S, Prince M, Prina AM. Prevalence of multimorbidity in community settings: a systematic review and meta-analysis of observational studies. J Comorbidity 2019; 9: 2235042 X1987093. https://doi.org/10.1177/2235042X19870934.

24. Ouzzani M, Hammad H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev 2016; 5: 210. https://doi.org/10.1186/s13643-016-0384-4.

25. Vegda K, Nie JX, Wang L, Tracy CS, Moineddin R, Upshur RIEG. Trends in health services utilization, medication use, and health conditions among older adults: a 2-year retrospective chart review in a primary care practice. BMC Health Serv Res 2009; 9: 1–7. https://doi.org/10.1186/1472-6963-9-217.

26. Gellert P, von Berenberg P, Zahn T, Neuwirth J, Kuhlmeys A, Dräger D. Multimorbidity profiles in German centenarians: a latent class analysis of health insurance data. J Aging Health 2019; 31: 580–94.

27. Rodrigues AM, Gregório MJ, Sousa RD et al. Challenges of ageing in Portugal: data from the EpiDoC cohort. Acta Med Port 2018; 31: 80–93.

28. Wang HHX, Wang JJ, Lawson KD et al. Relationships of multimorbidity and income with hospital admissions in 3 health care systems. Ann Fam Med 2015; 13: 164–7.

29. Pati S, Agrawal S, Swain S et al. Non communicable disease multimorbidity and associated health care utilization and expenditures in India: cross-sectional study. BMC Health Serv Res 2014; 14: 451. https://doi.org/10.1186/1472-6963-14-451.

30. Cassell A, Edwards D, Harshfield A et al. The epidemiology of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract 2018; 68: e245–51.

31. Sum G, Ishida M, Kob GC-H, Singh A, Oldenburg B, Lee JT. Implications of multimorbidity on healthcare utilization and work productivity by socioeconomic groups: cross-sectional analyses of Australia and Japan. PLoS One 2020; 15: e0232281. https://doi.org/10.1371/journal.pone.0232281.

32. Quinaz Romana G, Kislaya I, Cunha Gonçalves S, Salvador MR, Nunes B, Matias DC. Healthcare use in patients with multimorbidity. Eur J Public Health 2020; 30: 16–22.

33. Gong CH, Kendig H, He X. Factors predicting health services use among older people in China: an analysis of the China health and retirement longitudinal study 2013. BMC Health Serv Res 2016; 16: 63. https://doi.org/10.1186/s12913-016-1307-8.

34. Kim J, Keshavjee S, Atun R. Trends, patterns and health consequences of multimorbidity among South Korea adults: analysis of nationally representative survey data 2007-2016. J Glob Health 2020; 10: 20426. https://doi.org/10.7189/joghl.020426, https://pubmed.ncbi.nlm.nih.gov/33274056.

35. Frolich A, Ghith N, Schistz M, Jacobsen R, Stockmarr A. Multimorbidity, healthcare utilization and socioeconomic status: a register-based study in Denmark. PLoS One 2019; 14: e0214183. https://doi.org/10.1371/journal.pone.0214183.

36. Jankovic J, Mirkovic M, Jovic-Vranes A, Santric-Milicevic M, Terzic-Supic Z. Association between non-communicable disease multimorbidity and health care utilization in a middle-income country: population-based study. Public Health 2018; 155: 35–42.

37. Dantas I, Santana R, Sarmento J, Aguiar P. The impact of multiple chronic diseases on hospitalizations for ambulatory care sensitive conditions. BMC Health Serv Res 2016; 16: 348. https://doi.org/10.1186/s12913-016-1584-2, https://pubmed.ncbi.nlm.nih.gov/27488262.

38. Basu J, Avila R, Ricciardi R. Hospital readmission rates in U.S. states: are readmissions higher where more patients with multiple chronic conditions cluster? Health Serv Res 2016; 51: 1135–51.
Association between multimorbidity and hospitalization in older adults

39. Hempeast K, Delia D, Cantor JC, Nguyen T, Brenner J. The fragmentation of hospital use among a cohort of high utilizers: implications for emerging care coordination strategies for patients with multiple chronic conditions. Med Care 2014; 52: S67–74.

40. Wang HHX, Wang JJ, Wong SYS et al. Epidemiology of multimorbidity in China and implications for the healthcare system: cross-sectional survey among 162,464 community household residents in southern China. BMC Med 2014; 12: 188. https://doi.org/10.1186/s12916-014-0188-0.

41. Juul-Larsen HG, Christensen LD, Bandholm T et al. Patterns of multimorbidity and differences in healthcare utilization and complexity among acutely hospitalized medical patients (≥65 years) - a latent class approach. Clin Epidemiol 2020; Volume 12: 245–59.

42. Ahn S, Hussein M, Mahmood A, Smith ML. Emergency department and inpatient utilization among U.S. older adults with multiple chronic conditions: a post-reform update. BMC Health Serv Res 2020; 20: 77. https://doi.org/10.1186/s12913-020-4902-0.

43. Palladino R, Lee JT, Ashworth M, Triassi M, Millet C. Associations between multimorbidity, healthcare utilisation and health status: evidence from 16 European countries. Age Ageing 2016; 45: 431–5.

44. Palladino R, Pennino F, Finbarr M, Millet C, Triassi M. Multimorbidity and health outcomes in older adults in ten European health systems, 2006-15. Health Aff (Millwood) 2019; 38: 613–23.

45. World Bank. World Bank Country and Lending Groups [cited 2021 July 10]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519.

46. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998; 52: 377–84.

47. Noll M, Kjaer P, Mendonça CR, Wedderkopp N. Motor performance and back pain in children and adolescents: a systematic review. Eur J Pain 2022; 26: 77–102.

48. Balshem H, Helfand M, Schünemann HJ et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64: 401–6.

49. Grant RL. Converting an odds ratio to a range of plausible relative risks for better communication of research findings. BMJ 2014; 348: f7450. https://doi.org/10.1136/bmj.f7450.

50. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–58.

51. Kang EY, Park Y, Li X, Segré AV, Han B, Eskin E. ForestPM-Plot: a flexible tool for visualizing heterogeneity between studies in meta-analysis. G3 (Bethesda) 2016; 6: 1793–8.

52. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455–63.

53. Egger M,Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–34.

54. Wagner E, Patrick DL, Khandelwal N et al. The influence of multimorbidity on health care utilization at the end of life for patients with chronic conditions. J Palliat Med 2019; 22: 1260–5.

55. Navickas R, Visockienė Ž, Puronaitė R, Ručišienė M, Kasiulevičius V, Jurevičienė E. Prevalence and structure of multiple chronic conditions in Lithuanian population and the distribution of the associated healthcare resources. Eur J Intern Med 2015; 26: 160–8.

56. Mitsutake S, Ishizaki T, Teramoto C, Shimizu S, Ito H. Patterns of co-occurrence of chronic disease among older adults in Tokyo, Japan. Prev Chronic Dis 2019; 16: E11. https://doi.org/10.5888/pcd16.180170.

57. Gandhi K, Lim E, Davis J, Chen JJ. Racial disparities in health service utilization among Medicare fee-for-service beneficiaries adjusting for multiple chronic conditions. J Aging Health 2018; 30: 1224–43.

58. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002; 162: 2269–76.

59. Nágka K, Dong H-J, Marcusson J, Skoglund SO, Wressle E. Health-related factors associated with hospitalization for old people: comparisons of elderly aged 85 in a population cohort study. Arch Gerontol Geriatr 2012; 54: 391–7.

60. Glynn LG, Valderas JM, Healy P et al. The prevalence of multimorbidity in primary care and its effect on health care utilization and cost. Fam Pract 2011; 28: 516–23.

61. Picco L, Achilla E, Abdin E et al. Economic burden of multimorbidity among older adults: impact on healthcare and societal costs. BMC Health Serv Res 2016; 16: 173. https://doi.org/10.1186/s12913-016-1421-7.

62. Ensrud KE, Lui LY, Langsetmo L et al. Effects of mobility and multimorbidity on inpatient and Postacute health care utilization. J Gerontol A Biol Sci Med Sci 2018; 73: 1343–9.

63. Wister A, Kendig H, Mitchell B, Fyffe I, Loh V. Multimorbidity, health and aging in Canada and Australia: a tale of two countries. BMC Geriatr 2016; 16: 163. https://doi.org/10.1186/s12877-016-0341-z.

64. Conner KO, Meng H, Marino V, Boaz TL. Individual and organizational factors associated with hospital readmission rates: evidence from a U.S. National Sample. J Appl Gerontol 2020; 39: 1153–8.

65. Lochner KA, Goodman RA, Posner S, Parekh A. Multiple chronic conditions among Medicare beneficiaries: state-level variations in prevalence, utilization, and cost, 2011. Medicare Medicaid Rev Rev 2013; 3: E1–19. https://doi.org/10.5600/mmrr.003.03.b02.

66. Lai FTT, Wong SYS, Yip BHK et al. Multimorbidity in middle age predicts more subsequent hospital admissions than in older age: a nine-year retrospective cohort study of 121,188 discharged in-patients. Eur J Intern Med 2019; 61: 103–11.

67. García-Ramírez J, Nikoloski Z, Mossialos E. Inequality in healthcare use among older people in Colombia. Int J Equity Health 2020; 19: 168. https://doi.org/10.1186/s12939-020-01241-0.

68. Li C, Zhou R, Yao N, Cornwell T, Wang S. Health care utilization and unmet needs in Chinese older adults with multimorbidity and functional impairment. J Am Med Dir Assoc 2020; 21: 806–10.

69. Cheung JTY, Yu R, Wu Z, Wong SYS, Woo J. Geriatric syndromes, multimorbidity, and disability overlap and increase healthcare use among older Chinese. BMC Geriatr 2018; 18: 1–8. https://doi.org/10.1186/s12877-018-0840-1.

70. Wang XX, Chen ZB, Chen XJ et al. Functional status and annual hospitalization in multimorbidity and non-multimorbidity older adults: a cross-sectional study in southern China. Health Qual Life Outcomes 2018; 16: 33. https://doi.org/10.1186/s12955-018-0864-4.
71. Nunes BP, Soares MU, Wachs LS et al. Hospitalization in older adults: association with multimorbidity, primary health care and private health plan. Rev Saúde Pública 2017; 51: 1–9. https://doi.org/10.1590/s1518-8787.2017051006646.

72. Pati S, Swain S, Knottnerus JA, Metsemakers JFM, van den Akker M. Magnitude and determinants of multimorbidity and health care utilization among patients attending public versus private primary care: a cross-sectional study from Odisha, India. Int J Equity Health 2020; 19: 57. https://doi.org/10.1186/s12939-020-01170-y. https://pubmed.ncbi.nlm.nih.gov/32349770.

73. Collerton J, Jagger C, Yadegarfar ME et al. Deconstructing complex multimorbidity in the very old: findings from the Newcastle 85+ study. Biomed Res Int 2016; 2016: 1–15. https://doi.org/10.1155/2016/8745670.

74. Mini GK, Thankappan KR. Pattern, correlates and implications of non-communicable disease multimorbidity among older adults in selected Indian states: a cross-sectional study. BMJ Open 2017; 7: e013529. https://doi.org/10.1136/bmjopen-2016-013529.

75. Matthews T, Anindya K, Ng N et al. Impact of non-communicable disease multimorbidity on health service use, catastrophic health expenditure and productivity loss in Indonesia: a population-based panel data analysis study. BMJ Open 2021; 11: e041870. https://doi.org/10.1136/bmjopen-2020-041870.

76. Gruneir A, Bronskill SE, Maxwell CJ et al. The association between multimorbidity and hospitalization is modified by individual demographics and physician continuity of care: a retrospective cohort study. BMC Health Serv Res 2016; 16: 154. https://doi.org/10.1186/s12913-016-1415-5.

77. Shesheshi DS, Dolja-Gore X, Byles J. Unplanned readmission within 28 days of hospital discharge in a longitudinal population-based cohort of older Australian women. Int J Environ Res Public Health 2020; 17: 3136. https://doi.org/10.3390/ijerph17093136.

78. Buja A, Rivera M, De Battisti E et al. Multimorbidity and hospital admissions in high-need, high-cost elderly patients. J Aging Health 2020; 32: 259–68.

79. Chamberlain AM, Rutten LJF, Jacobson DJ et al. Multimorbidity, functional limitations, and outcomes: interactions in a population-based cohort of older adults. Journal of multimorbidity and comorbidity 2019; 9: 2235042X1987348. https://doi.org/10.1177/2235042X19873486.

80. Halonen P, Raitanen J, Jämsen E, Entroh L, Jylhä M. Chronic conditions and multimorbidity in population aged 90 years and over: associations with mortality and long-term care admission. Age Ageing 2019; 48: 564–70.

81. Aubert CE, Fankhauser N, Marques-Vidal P et al. Multimorbidity and healthcare resource utilization in Switzerland: a multicentre cohort study. BMC Health Serv Res 2019; 19: 708. https://doi.org/10.1186/s12913-019-4575-2.

82. Nunes BP, Thumé E, Facchinetti LA. Multimorbidity in older adults: magnitude and challenges for the Brazilian health system chronic disease epidemiology. BMC Public Health 2015; 15: 1–11. https://doi.org/10.1186/s12889-015-2505-8.

83. Mercer S, Furler J, Moffat K, Fischbacher-Smith D, Sancl L. Multimorbidity: technical series on safer primary care. Geneva: World Health Organization, 2016.

84. Arbix G. Ciência e tecnologia em um mundo de ponta-cabeça. Estud av 2020; 34: 65–76.

85. Tisminetzky M, Delude C, Hebert T, Carr C, Goldberg RJ, Gurwitz JH. Age, multiple chronic conditions, and COVID-19: a literature review. J Gerontol A Biol Sci Med Sci 2022; 77: 872–8.

86. Ticinesi A, Nouvenne A, Cerundolo N et al. Trends of COVID-19 admissions in an Italian hub during the pandemic peak: large retrospective study focused on older subjects. J Clin Med 2021; 10: 1115. https://doi.org/10.3390/jcm10051115.

87. Calderón-Larrañaga A, Vetrano DL, Onder G et al. Assessing and measuring chronic multimorbidity in the older population: a proposal for its operationalization. J Gerontol A Biol Sci Med Sci 2017; 72: glw233–1423.

88. De Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003; 57: 323–229.

89. Diederichs C, Berger K, Bartels DB. The measurement of multiple chronic diseases—a systematic review on existing multimorbidity indices. J Gerontol A Biol Sci Med Sci 2011; 66: 301–11.